Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Gravesâ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Employees

207

Sector

Biotechnology & Medical Research

Calendar

31/10/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
17/09/24	29.08 $	-1.19%	386,897
16/09/24	29.43 $	-0.81%	984,038
13/09/24	29.67 $	+2.81%	963,116
12/09/24	28.86 $	-0.65%	1,147,271
11/09/24	29.05 $	-2.25%	910,435

Delayed Quote Nasdaq, September 16, 2024 at 09:00 pm

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.43USD

Average target price

49.07USD

Spread / Average Target

+66.74%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 19:23:32 17/09/2024 BST			5-day change	1st Jan Change
28.98 ^USD	-1.51%		-2.05%	-30.90%

09-09	Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained	MT
09-09	Transcript : Immunovant, Inc. - Special Call

Capitalization	4.31B 326B	P/E ratio 2025 *	-12x	P/E ratio 2026 *	-12x
Enterprise value	4.06B 307B	EV / Sales 2025 *	-	EV / Sales 2026 *	70.3x
Free-Float	42.86%	Yield 2025 *	-	Yield 2026 *	-

Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained	09-09	MT
Transcript : Immunovant, Inc. - Special Call	09-09
Immunovant, Inc. Provides Update on Graves' Disease Development Program	09-09	CI
Immunovant's Graves' Disease Drug Shows Improved Efficacy at Higher Doses	09-09	MT
Immunovant Insider Sold Shares Worth $480,052, According to a Recent SEC Filing	08-23	MT
UBS Trims Price Target on Immunovant to $41 From $42, Maintains Buy Rating	08-13	MT
Earnings Flash (IMVT) IMMUNOVANT Reports Q2 Loss $-0.60	08-06	MT
Immunovant, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2024	08-06	CI
Immunovant Insider Sold Shares Worth $257,888, According to a Recent SEC Filing	07-19	MT
Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating	06-03	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	05-30	MT
Immunovant Q4 Loss Widens -- Shares Fall After-Hours	05-29	MT
Immunovant, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	05-29	CI

Citigroup Raises Immunovant's Price Target to $60 From $51, Buy Rating Maintained	09-09	MT
UBS Trims Price Target on Immunovant to $41 From $42, Maintains Buy Rating	08-13	MT
Immunovant Insider Sold Shares Worth $257,888, According to a Recent SEC Filing	07-19	MT
Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating	06-03	MT
Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing	05-24	MT

Immunovant, Inc. Share Price

Equities

IMVT

US45258J1025

Biotechnology & Medical Research

Valuation: Immunovant, Inc.

Chart: Immunovant, Inc.

Latest news: Immunovant, Inc.

Last Transcript: Immunovant, Inc.

Analysts' recommendations: Immunovant, Inc.

Press Releases: Immunovant, Inc.

News in other languages: Immunovant, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Immunovant, Inc.

ETFs: Immunovant, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly earnings, Rate of surprise

Immunovant Provides Update on graves disease Development Program	09-10	AQ
Roivant Provides Update on Graves’ Disease Development Program	09-09	AQ
Immunovant Provides Update on Graves’ Disease Development Program	09-09	AQ
Immunovant to Host Graves’ Disease Program Update on September 9, 2024	09-05	AQ
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024	08-06	AQ

Bel20 terug in het rood ondanks koersherstel Argenx	27/09/23
Argenx en Lotus uitblinkers	27/09/23
Argenx leidt Bel20 hoger	27/09/23
Koersdaling Argenx koopkans	27/09/23
Las acciones de Immunovant se disparan datos alentadores sobre tratamiento con anticuerpos	26/09/23

1 day	-0.81%
1 week	-6.39%
Current month	-4.76%
1 month	-2.06%
3 months	+13.19%
6 months	-3.60%
Current year	-30.14%

Director	Title	Age	Since
Peter Salzmann CEO	Chief Executive Officer	56	31/05/19
Eva Barnett DFI	Director of Finance/CFO	44	03/10/21
Michael Geffner CTO	Chief Tech/Sci/R&D Officer	55	-

Manager	Title	Age	Since
Frank Torti CHM	Chairman	45	17/12/19
Andrew Fromkin BRD	Director/Board Member	58	17/12/19
George Migausky BRD	Director/Board Member	69	17/12/19

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	0.09%	0 M€	0.00%	-
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	0.04%	2 M€	-.--%
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	0.02%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
IMMUNOVANT, INC.	-0.81%	-6.39%	+34.94%	+246.64%	4.31B
LONZA GROUP AG	-0.15%	+0.55%	+29.72%	-26.89%	47.07B
IQVIA HOLDINGS INC.	+0.28%	-0.62%	+13.07%	-7.16%	43.64B
ALNYLAM PHARMACEUTICALS, INC.	+1.92%	+6.80%	+46.15%	+42.15%	34.71B
CELLTRION, INC.	-0.20%	+1.61%	+33.24%	-22.45%	30.52B
MODERNA, INC.	+1.30%	-9.71%	-39.64%	-84.30%	26.59B
ICON PUBLIC LIMITED COMPANY	-1.47%	-1.04%	+12.94%	+9.17%	24.48B
UNITED THERAPEUTICS CORPORATION	+1.73%	-1.07%	+56.64%	+68.17%	15.35B
BIO-TECHNE CORPORATION	+0.12%	+3.70%	+1.51%	-43.52%	11.86B
MEDPACE HOLDINGS, INC.	+1.43%	+5.10%	+27.40%	+93.06%	11.03B
Average	+0.37%	-0.02%	+21.60%	+27.49%	24.96B
Weighted average by Cap.	+0.37%	+0.39%	+20.79%	-0.79%

	2025 *	2026 *
Net sales	-	56.52M 4.28B
Net income	-370M -27.97B	-391M -29.57B
Net Debt	-585M -44.3B	-331M -25.06B